Search Results 1-10 of 8535 for TNF

  1. Mayo Clinic Researchers: TNF Inhibitors May Increase Cancer Risk in the Eye

    They act by dampening part of the immune system called tumor necrosis factor (TNF). In one of the balancing acts of medicine, the anti-inflammatory action of ...

  2. Rheumatoid arthritis finding may lead to new inflammation blockers - Mayo Clinic News Network

    Rheumatoid arthritis is an autoimmune disorder characterized by chronic inflammation, including high levels of a cytokine called tumor necrosis factor, or TNF.

  3. Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy - Mayo Clinic

    Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy · Overview · Participation eligibility.

  4. Examining clinical and genetic factors that impact response to anti-TNF agents in patients with IBD

    Approved in 1998 for use in treating Crohn's disease and subsequently in 2005 for treating ulcerative colitis, anti-tumor necrosis factor (TNF) agents have ...

  5. A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy - Mayo Clinic

    ... Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy ... TNF Therapy. Amended Protocol to Include a Lutikizumab Open-Label Sub-study ...

  6. A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy - Mayo Clinic

    ... tumor necrosis factor (TNF) therapy. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous ...

  7. A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Participants Who Are Refractory to or Intolerant of Tumor Necrosis Factor (TNF) Inhibitors - Mayo Clinic

    A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Participants Who Are Refractory to or Intolerant of Tumor Necrosis Factor (TNF) ...

  8. Mayo Clinic researchers to present study findings at American College of Gastroenterologists Annual Scientific Meeting

    Pardi. Anti-tumor necrosis factor (TNF) therapy linked to preeclampsia in women with inflammatory bowel disease. Women with inflammatory bowel disease have ...

  9. Study to Determine Risk Factors for Post-operative Infection in Inflammatory Bowel Disease - Mayo Clinic

    ... Tumor Necrosis Factor (anti-TNF) agents infliximab, adalimumab, and certolizumab. However, many CD and UC patients still ultimately require surgery despite ...

  10. Study to Determine Risk Factors for Post-operative Infection in Inflammatory Bowel Disease - Mayo Clinic

    ... Tumor Necrosis Factor (anti-TNF) agents infliximab, adalimumab, and certolizumab. However, many CD and UC patients still ultimately require surgery despite ...